Collegium Pharmaceutical (COLL) vs Design Therapeutics (DSGN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Design Therapeutics (DSGN) has outperformed Collegium Pharmaceutical (COLL) over the past year, gaining 80.1% versus a loss of 34.3%. Over five years, COLL leads with a +4.5% price change compared with -18.0% for DSGN. Design Therapeutics is the larger company by market cap ($731.6 million vs $713.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | COLL | DSGN |
|---|---|---|
| Share price | $21.93 | $11.69 |
| Market cap | $713.94M | $731.58M |
| 1-day change | +0.23% | -2.34% |
| YTD return | -52.63% | +24.63% |
| 1-year return | -34.32% | +80.12% |
| 5-year return | +4.53% | -17.96% |
| P/E ratio (TTM) | 17.27 | — |
| Forward P/E | 3.30 | — |
| EPS (TTM) | $1.27 | $-1.18 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $50.79 | $17.25 |
| 52-week low | $21.43 | $5.28 |
| Distance from 52-week high | -56.82% | -32.23% |
| Average volume | 743.01K | 614.39K |
| Shares outstanding | 32.56M | 62.58M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DSGN has outperformed COLL by 114.4 percentage points over the past year.
COLL vs DSGN FAQ
Which is bigger, Collegium Pharmaceutical or Design Therapeutics?
Design Therapeutics (DSGN) is larger, with a market capitalization of $731.58M compared with $713.94M for Collegium Pharmaceutical (COLL).
Which stock has performed better over the past year, COLL or DSGN?
DSGN returned +80.12% over the past 12 months, compared with -34.32% for COLL (price return, excluding dividends). Past performance does not predict future results.
Are Collegium Pharmaceutical and Design Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.